

## **ASX Announcement**

# Dispatch of Prospectus and Entitlement Offer Open

On 25 May 2023, Wellnex Life Limited (ASX: **WNX**) (**Wellnex** or **Company**) announced that it is conducting a pro-rata non-renounceable entitlement offer of new fully paid ordinary shares (**Shares**), which entitles eligible shareholders to subscribe for 1 new Share for every 4 Shares held on the record date of 7.00pm (AEST) on Monday 19 June 2023, at an issue price of \$0.05 per new Share (**Entitlement Offer**). The Entitlement Offer is being made pursuant to a prospectus, a copy of which was lodged with ASIC and ASX, and made available on the Company's website, on 13 June 2023 (**Prospectus**).

The Entitlement Offer opened **today**, Thursday 22 June 2023, and will close at 5.00pm (AEST) on 12 July 2023 (unless extended).

Wellnex confirms that the following documents were dispatched today:

- For all eligible shareholders who have nominated to receive documents from Wellnex electronically, an email providing access to the Prospectus and personalised entitlement and acceptance form by electronic means;
- For all other eligible shareholders, a letter via post notifying them of the Entitlement Offer and providing instructions on how to access the Prospectus and their personalised entitlement and acceptance form online; and
- For all ineligible retail shareholders, a letter notifying them of the Entitlement Offer and their ineligibility to participate in the Entitlement Offer.

#### **Further information**

For further information about the Entitlement Offer, please contact the Company's share registry, Computershare Investor Services Pty Limited, on 1300 850 505 within Australia and +61 (3) 9415 4000 outside Australia.

-ENDS-

#### Further information:

Investor & Media Relations Sophie Bradley Reach Markets Email: IR@reachmarkets.com.au Phone: 1300 805 795 Financial Advisor Ryan Legudi Salter Brothers Email: <u>ryan.legudi@salterbrothers.com.au</u> Phone: 03 9258 2100



### About Wellnex Life:

Wellnex Life Limited (ASX: WNX) is a consumer healthcare business that specialises in developing and licensing healthcare brands and products to bring to market. Listed in 2021, Wellnex has successfully launched and licensed cutting-edge brands in emerging specialty categories and has established key partnerships and agreements with leading companies in the Australian and global health space. Wellnex is focused on building a portfolio of brands and businesses that can improve the health of consumers, that will ultimately create value for shareholders.

To stay up to date with news & announcements, register your details on the Wellnex Life investor portal.